ERYTECH Pharma S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ERYTECH Pharma S.A.
French Biotech In Focus: While R&D at French biopharma firms in general reflects worldwide trends for oncology and neurology, rare diseases are coming more to the fore, backed by the country’s world-class academic institutions and US FDA recognition.
Rafael’s lead drug candidate has failed in a Phase III trial for pancreatic cancer and the company has been advised to stop a Phase III study of the product in AML.
Erytech’s eryaspase has failed in its Phase III TRYbeCA-1 trial for second-line pancreatic cancer despite analyst excitement for the solid tumor indication. Its attentions now turn, once again, to its acute lymphoblastic leukemia indication.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.
- Other Names / Subsidiaries
- ERYTECH Pharma, Inc.